Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Luteal phase defects

B Bopp1, D Shoupe

  • 1Department of Obstetrics and Gynecology, University of Southern California School of Medicine, Los Angeles.

The Journal of Reproductive Medicine
|May 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hormone replacement therapy: consensus and controversies.

Panminerva medica·2014
Same author

Individualizing hormone-therapy according to cardiovascular risk.

Minerva ginecologica·2013
Same author

Individualizing hormone-therapy according to cardiovascular risk.

Minerva medica·2012
Same author

Comparison of estrogen and androgen levels after oral estrogen replacement therapy.

The Journal of reproductive medicine·2002
Same author

Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial.

Annals of internal medicine·2001
Same author

Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate.

Fertility and sterility·2001
Same journal

Elective Procedures in Obstetrics and Gynecology During the COVID-19 Pandemic.

The Journal of reproductive medicine·2022
Same journal

Choriocarcinoma in Situ in a Partial Hydatidiform Mole A: Case Report.

The Journal of reproductive medicine·2018
Same journal

Isolated Recurrent Hematotrachelos After Abdominal Myomectomy A Case Report.

The Journal of reproductive medicine·2018
Same journal

Live Birth from Electively Cryopreserved Oocytes: A Feasible Option for Couples Opposed to Embryo Cryopreservation A Case Report.

The Journal of reproductive medicine·2018
Same journal

Prevalence and Risk Factors of Ejaculation Failure on the Day of Operation Among Chinese Males Undergoing Assisted Reproductive Technique Treatments.

The Journal of reproductive medicine·2018
Same journal

Efficacy and Safety of Perioperative Use of Epinephrine for Laparoscopic Myomectomy in Infertile Women with Symptomatic Solitary Intramural Uterine Fibroids A Randomized Clinical Trial.

The Journal of reproductive medicine·2018
See all related articles

Luteal phase defects, characterized by insufficient progesterone, affect infertile couples. Diagnosis involves progesterone testing, with clomiphene citrate recommended as the primary treatment.

Area of Science:

  • Reproductive Endocrinology
  • Infertility Research

Background:

  • Luteal phase defects (LPD) stem from inadequate corpus luteum function and progesterone production.
  • LPD may impact 3-4% of infertile couples, particularly those with unexplained infertility or recurrent pregnancy loss.

Purpose of the Study:

  • To outline diagnostic criteria for luteal phase defects.
  • To review available treatment options for luteal phase defects.

Main Methods:

  • Diagnosis is suggested by mid-luteal serum progesterone levels below 10 ng/mL, confirmed via blood tests 7-9 days post-ovulation.
  • Endometrial biopsies are recommended for unexplained infertility or recurrent abortion, especially with progesterone levels above 10 ng/mL.

Main Results:

Related Experiment Videos

  • A progesterone level < 10 ng/mL is indicative of a luteal phase defect.
  • Endometrial biopsy is a key diagnostic tool in specific patient groups.

    • Conclusions:

    • Clomiphene citrate, progesterone vaginal suppositories, human menopausal gonadotropins, and bromocriptine are treatment options.
    • Clomiphene citrate is the preferred first-line treatment due to its ease of use.